‘Modest’ expectations for ‘21 sales of Biogen’s Aduhelm

Biogen is seeing “strong indications of very high initial patient interest” in Aduhelm, CEO Michel Vounatsos said on the company’s 2Q21 earnings call Thursday, but the company expects modest revenues for the Alzheimer’s drug this year.

Sales of Aduhelm aducanumab-avwa have reached $2 million following its approval June 7, with $1.6 million of that coming in the quarter’s final weeks...